Qiagen N.V. (QGEN)

NL — Healthcare Sector
Peers: SHC  NEOG  RDNT  MYGN  TECH  BIO  CRL  ALNY 

Automate Your Wheel Strategy on QGEN

With Tiblio's Option Bot, you can configure your own wheel strategy including QGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol QGEN
  • Rev/Share 9.4205
  • Book/Share 16.1874
  • PB 3.0351
  • Debt/Equity 0.4119
  • CurrentRatio 1.6121
  • ROIC 0.0681

 

  • MktCap 10639396280.0
  • FreeCF/Share 2.2919
  • PFCF 21.4365
  • PE 28.4944
  • Debt/Assets 0.248
  • DivYield 0.0256
  • ROE 0.1066

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation QGEN Barclays -- Overweight -- $55 June 24, 2025
Downgrade QGEN Redburn Atlantic Buy Neutral -- -- April 4, 2025
Downgrade QGEN Robert W. Baird Outperform Neutral $52 $42 Feb. 19, 2025
Downgrade QGEN Morgan Stanley Overweight Equal Weight -- $48 Jan. 6, 2025
Upgrade QGEN Jefferies Hold Buy $42.5 $54 Dec. 10, 2024
Downgrade QGEN HSBC Securities Buy Hold -- $49 Oct. 17, 2024

News

Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
QGEN
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
QGEN
Published: April 08, 2025 by: Business Wire
Sentiment: Neutral

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect.

Read More
image for news QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
QGEN
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.

Read More
image for news Qiagen N.V.: Some Clarity Needed Before Buying The Dip

About Qiagen N.V. (QGEN)

  • IPO Date 1996-06-28
  • Website https://www.qiagen.com
  • Industry Medical - Diagnostics & Research
  • CEO Thierry Bernard
  • Employees 5700
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.